Skip to main content
Year archive

Compugen Ltd. — 2023 filings

All 94 regulatory filings released by Compugen Ltd. (CGEN) in 2023, sourced directly from the official regulator.

94 Filings
2023 Period
2023 filings (94)
Filing Released Lang
6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca
Regulatory Filings
2023-12-19 English
6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca
Report Publication Announcement
2023-12-19 English
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Regulatory Filings
2023-12-19 English
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Report Publication Announcement
2023-12-19 English
to Host Conference Call to Discuss Exclusive License Agreement with Gilead
Regulatory Filings
2023-12-19 English
to Host Conference Call to Discuss Exclusive License Agreement with Gilead
Report Publication Announcement
2023-12-19 English
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
M&A Activity
2023-12-19 English
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Report Publication Announcement
2023-12-19 English
Compugen Reports Third Quarter 2023 Results
Earnings Release Q3 2023
2023-11-07 English
Compugen Reports Third Quarter 2023 Results
Report Publication Announcement
2023-11-07 English
Compugen’s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
Regulatory Filings
2023-11-06 English
Compugen’s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
Report Publication Announcement
2023-11-06 English
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings
2023-11-03 English
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
Report Publication Announcement
2023-11-03 English
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of AntiIL18 Binding Protein Antibody, COM503, in Treating Cancer
Investor Presentation
2023-10-31 English
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of AntiIL18 Binding Protein Antibody, COM503, in Treating Cancer
Report Publication Announcement
2023-10-31 English
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023,Management will host a conference call to review the results at 8:30 AM ET
Report Publication Announcement
2023-10-24 English
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023,Management will host a conference call to review the results at 8:30 AM ET
Report Publication Announcement
2023-10-24 English
Compugen to Present at Single Cell Genomics 2023 Meeting
Regulatory Filings
2023-10-03 English
Compugen to Present at Single Cell Genomics 2023 Meeting
Report Publication Announcement
2023-10-03 English
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Regulatory Filings
2023-10-02 English
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Report Publication Announcement
2023-10-02 English
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
Regulatory Filings
2023-09-27 English
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
Report Publication Announcement
2023-09-27 English
Results of the Annual General Meeting of Shareholders held on September 20, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-09-21 English
Results of the Annual General Meeting of Shareholders held on September 20, 2023
Report Publication Announcement
2023-09-21 English
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Report Publication Announcement
2023-08-31 English
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Report Publication Announcement
2023-08-31 English
Form 20-F/A For the fiscal year ended December 31, 2022
Annual Report FY 2022
2023-08-23 English
Form 20-F/A For the fiscal year ended December 31, 2022
Report Publication Announcement
2023-08-23 English
2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, SEPTEMBER 20, 2023
Proxy Solicitation & Information Statement
2023-08-07 English
2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, SEPTEMBER 20, 2023
AGM Information
2023-08-07 English
Second Quarter 2023 Results
Interim / Quarterly Report Q2 2023
2023-08-07 English
Second Quarter 2023 Results
Report Publication Announcement
2023-08-07 English
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
Report Publication Announcement
2023-07-24 English
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
Report Publication Announcement
2023-07-24 English
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
Regulatory Filings
2023-07-17 English
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
Report Publication Announcement
2023-07-17 English
Amendment No. 2 to FORM F-3
Capital/Financing Update
2023-06-24 English
Amendment No. 2 to FORM F-3
Report Publication Announcement
2023-06-24 English
First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Stud
Regulatory Filings
2023-06-22 English
First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Stud
Report Publication Announcement
2023-06-22 English
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Regulatory Filings
2023-06-13 English
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Report Publication Announcement
2023-06-13 English
Compugen’s COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
Regulatory Filings
2023-06-05 English
Compugen’s COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
Report Publication Announcement
2023-06-05 English
Form 6-K- First Quarter 2023 Results
Interim / Quarterly Report Q1 2023
2023-05-15 English
Form 6-K- First Quarter 2023 Results
Report Publication Announcement
2023-05-15 English
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
Regulatory Filings
2023-05-11 English
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
Report Publication Announcement
2023-05-11 English
Compugen to Present at the JMP Securities Life Sciences Conference
Regulatory Filings
2023-05-09 English
Compugen to Present at the JMP Securities Life Sciences Conference
Report Publication Announcement
2023-05-09 English
Nasdaq granted the Company a second period of 180 calendar days, or until October 30, 2023, to regain compliance with the Minimum Bid Price Requirement for continued listing
Regulatory Filings
2023-05-03 English
Nasdaq granted the Company a second period of 180 calendar days, or until October 30, 2023, to regain compliance with the Minimum Bid Price Requirement for continued listing
Report Publication Announcement
2023-05-03 English
to Release First Quarter 2023 Results and conference call on Monday, May 15, 2023
Report Publication Announcement
2023-05-01 English
to Release First Quarter 2023 Results and conference call on Monday, May 15, 2023
Report Publication Announcement
2023-05-01 English
Compugen to Present New Clinical Data Showing Preliminary AntiTumor Activity of COM701 Triple Combination in Recurrent MSSMetastatic Endometrial Cancer at ASCO 2023
Regulatory Filings
2023-04-27 English
Compugen to Present New Clinical Data Showing Preliminary AntiTumor Activity of COM701 Triple Combination in Recurrent MSSMetastatic Endometrial Cancer at ASCO 2023
Report Publication Announcement
2023-04-27 English
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meetin
Regulatory Filings
2023-04-26 English
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meetin
Report Publication Announcement
2023-04-26 English
FORM F-3-mendment No. 1-TO PROSPECTUS Dated April 14, 2023
Regulatory Filings
2023-04-15 English
FORM F-3-mendment No. 1-TO PROSPECTUS Dated April 14, 2023
Regulatory Filings
2023-04-15 English
Amendment No. 1 to Form F-2 TO PROSPECTUS Dated April 14, 2023
Regulatory Filings
2023-04-15 English
Amendment No. 1 to Form F-2 TO PROSPECTUS Dated April 14, 2023
Report Publication Announcement
2023-04-15 English
FORM F-3-REGISTRATION STATEMENT
Transaction in Own Shares
2023-03-31 English
FORM F-3-REGISTRATION STATEMENT
Report Publication Announcement
2023-03-31 English
קומפיוג'ן מציגה מחקר חדש שמאפשר זיהוי מדויק של PVRIG בכנס של האגודה האמריקנית לחקר הסרטן
Regulatory Filings
2023-03-15 English
קומפיוג'ן מציגה מחקר חדש שמאפשר זיהוי מדויק של PVRIG בכנס של האגודה האמריקנית לחקר הסרטן
Report Publication Announcement
2023-03-15 English
Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation
Regulatory Filings
2023-03-11 English
Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation
Report Publication Announcement
2023-03-11 English
Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
Regulatory Filings
2023-03-08 English
Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
Report Publication Announcement
2023-03-08 English
Compugen Doses First Patient in Triple Combination COM701,COM902 and Pembrolizumab MSS CRC Proof of Concept Study
Regulatory Filings
2023-03-06 English
Compugen Doses First Patient in Triple Combination COM701,COM902 and Pembrolizumab MSS CRC Proof of Concept Study
Report Publication Announcement
2023-03-06 English
FORM 20-F For the fiscal year ended December 31, 2022
Annual Report FY 2022
2023-02-28 English
FORM 20-F For the fiscal year ended December 31, 2022
Report Publication Announcement
2023-02-28 English
Form 6-K- Fourth Quarter and Full Year 2022 Results
Earnings Release FY 2022
2023-02-27 English
Form 6-K- Fourth Quarter and Full Year 2022 Results
Report Publication Announcement
2023-02-27 English
Form 6-K- Rilvegostomig, AstraZeneca’s Bi-specific Antibody Derived from Compugen’s COM902, Expected to Progress into Phase 3
Regulatory Filings
2023-02-14 English
Form 6-K- Rilvegostomig, AstraZeneca’s Bi-specific Antibody Derived from Compugen’s COM902, Expected to Progress into Phase 3
Report Publication Announcement
2023-02-14 English
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023
Report Publication Announcement
2023-02-13 English
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023
Report Publication Announcement
2023-02-13 English
Schedule 13G/A filed by Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc.
Major Shareholding Notification
2023-02-13 English
Schedule 13G/A filed by Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc.
Regulatory Filings
2023-02-13 English
קומפיוגן תציג בכנס הביופארמה הגלובלי של SVB
Report Publication Announcement
2023-02-09 English
קומפיוגן תציג בכנס הביופארמה הגלובלי של SVB
Report Publication Announcement
2023-02-09 English
Schedule 13G/A filed by Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Co., Ltd
Major Shareholding Notification
2023-02-05 English
Schedule 13G/A filed by Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Co., Ltd
Regulatory Filings
2023-02-05 English
Entered into a Sales Agreement pursuant to which the company may offer and sell up to $50 million ordinary shares under the ATM plan
Regulatory Filings
2023-02-01 English
Entered into a Sales Agreement pursuant to which the company may offer and sell up to $50 million ordinary shares under the ATM plan
Regulatory Filings
2023-02-01 English
Prospectus Supplement relating to the sale of up to $50,000,000 ordinary shares from time to time
Capital/Financing Update
2023-02-01 English
Prospectus Supplement relating to the sale of up to $50,000,000 ordinary shares from time to time
Regulatory Filings
2023-02-01 English
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
Regulatory Filings
2023-01-23 English
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
Report Publication Announcement
2023-01-23 English